source
- Entrada Therapeutics shares plunge after Duchenne trial shows modest dystrophin increaseEntrada Therapeutics reported early data from a Phase 1/2 study of its RNA‑based therapy ENTR‑601‑44 for Duchenne muscular dystrophy, noting favorable safety and tolerability. The trial showed a d…
- Roche to acquire digital pathology firm PathAI in deal potentially worth over $1BRoche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.